CEO Buys 100,000 Shares Amid 81% Stock Decline at CEL‑SCI Corp.

CEO Buys 100,000 Shares Amid a Sharp Decline On May 13, 2026, KERSTEN GEERT R, the chief executive of CEL‑SCI Corp, purchased 100,000 shares of the company’s common stock at $1.19, the most recent closing price. This trade comes after a series of modest purchases by the CEO over the past year, most notably a large option purchase in July 2025 and a significant share acquisition in March 2025. The purchase raises questions about the CEO’s confidence in a company whose share price has fallen 81 % year‑to‑date and is trading near its 52‑week low of $0.89.

Implications for Investors A top‑executive buy in a company with a negative price‑earnings ratio and a declining market cap can be a double‑edged signal. On the one hand, insider buying may suggest that the CEO believes the stock is undervalued or that recent developments—such as the announced partnership with Multikine—will unlock future upside. On the other hand, the price level and the company’s weak fundamentals (negative P/E, steep weekly and monthly drops) caution investors to weigh the risk that the buy could simply be a short‑term hedge or a liquidity need rather than a long‑term bet. Analysts will likely scrutinize whether this purchase is part of a broader insider‑investment strategy or an isolated move.

What the Buying Pattern Says About Leadership GEERT’s purchase history shows a pattern of gradual accumulation rather than large, market‑moving trades. His first sizable buy in March 2025 (22,786 shares at $0.23) set a baseline of roughly 1.24 million shares, followed by incremental purchases in July and January of 2026. The recent 100,000‑share buy at $1.19 is the highest dollar amount the CEO has paid per share in over a year, indicating a willingness to pay a premium in hopes of a rebound. Historically, the CEO has favored restricted stock over options, suggesting a preference for ownership that aligns long‑term incentives with company performance.

Future Outlook for CEL‑SCI The CEO’s recent purchase, coupled with the company’s updated filing status and partnership announcement, points to a potential turning point. If the partnership with Multikine leads to new product pipelines or market expansion, the stock could see a gradual recovery. However, investors should monitor upcoming quarterly earnings, regulatory approvals, and any further insider activity. The current trend of insider buying is a positive but modest signal; it must be weighed against the broader backdrop of a distressed biotech firm operating in a highly competitive sector.